MyFinsight
Home
Blog
About
Sales and maturities
of marketable...
$48,674K
(-67.39%↓ Y/Y)
Exercise of stock options
$546K
Net cash flows
provided by investing...
$12,806K
(-72.67%↓ Y/Y)
Net cash flows (used
in) provided by...
$541K
(2180.77%↑ Y/Y)
Canceled cashflow
$35,868K
Canceled cashflow
$5K
Net change in cash
and cash...
-$27,027K
(-90.60%↓ Y/Y)
Canceled cashflow
$13,347K
Equity-based compensation
$5,594K
(-56.83%↓ Y/Y)
Prepaid and other assets
-$1,678K
(76.70%↑ Y/Y)
Depreciation and
amortization
$1,678K
(-45.25%↓ Y/Y)
Interest receivable
-$76K
(88.69%↑ Y/Y)
Purchases of marketable
securities
$32,035K
(-67.36%↓ Y/Y)
Purchase of equipment and
facility expansion
$3,833K
(-9.75%↓ Y/Y)
Payments on finance
leases
$5K
(-80.77%↓ Y/Y)
Net cash flows used
in operating...
-$40,374K
(33.82%↑ Y/Y)
Canceled cashflow
$9,026K
Net loss before
noncontrolling interest
-$46,436K
(38.02%↑ Y/Y)
Accounts payable and
accrued expenses
-$2,708K
(66.67%↑ Y/Y)
Gain on marketable
securities, net
$256K
(-86.82%↓ Y/Y)
Back
Back
Cash Flow
PROKIDNEY CORP. (PROK)
PROKIDNEY CORP. (PROK)
source: myfinsight.com